Equities

Genflow Biosciences PLC

Genflow Biosciences PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.80
  • Today's Change0.00 / 0.00%
  • Shares traded432.01k
  • 1 Year change+12.50%
  • Beta--
Data delayed at least 20 minutes, as of Nov 12 2024 16:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.53m
  • Incorporated2021
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ovoca Bio PLC0.00-3.29m1.59m5.00--0.8573-----0.0388-0.03470.000.0210.00----0.00-88.55-25.19-100.85-27.65------------0.00------9.05------
ValiRx Plc9.60k-1.97m2.02m8.00--0.5245--210.24-0.0172-0.01720.000080.02910.0025--0.0639---53.19-50.57-51.14-54.7785.00---21,512.29-103,908.506.27--0.0048------13.89---1.13--
TheraCryf PLC396.00k-3.14m2.56m9.00--0.7045--6.47-0.0114-0.01140.00140.00850.0858--0.976644,000.00-67.93-42.50-81.69-46.66-----792.17-1,482.46----0.00---10.41--22.41------
N4 Pharma PLC5.86k-1.12m2.57m5.00--2.05--437.90-0.0042-0.00420.000020.00320.0041--0.04211,172.00-79.19-57.05-83.28-61.13-----19,152.56-309,312.80---3,023.170.00-----51.52-24.05------
Fusion Antibodies PLC1.14m-2.23m3.98m31.00--2.21--3.51-0.0426-0.04260.02050.01880.50692.362.0236,645.16-99.33-41.50-147.47-52.23-3.9640.19-195.95-56.923.09-1,144.000.0234---60.84-12.2414.25---72.95--
Genflow Biosciences PLC0.00-1.53m6.29m5.00--7.33-----0.0051-0.00510.000.00250.00----0.00-93.85---118.87--------------0.00-------21.97------
ImmuPharma PLC-69.96k-2.46m6.88m5.00--2.56-----0.0065-0.0065-0.00020.0065-0.019-----13,992.00-66.99-86.13-111.20-106.39-------8,634.98---7.270.00------23.26------
LungLife AI Inc22.53k-3.47m7.23m15.00--0.3528--321.01-0.1304-0.13040.00080.24190.0027--2.901,502.32-42.18---47.78--100.00---15,403.45------0.0259--91.67--28.83------
Cizzle Biotechnology Holdings PLC0.00-2.70m7.53m67.00--9.49-----0.0073-0.00730.000.0020.00-------146.70-144.15-157.81-167.75-----------0.450.00-------88.27------
IXICO PLC6.00m-1.87m8.11m89.00--0.4215--1.35-0.0386-0.03860.12410.20760.4725--3.5467,415.73-14.694.35-16.585.3346.9062.09-31.106.61----0.03120.00-22.894.32-214.15--92.12--
Synairgen plc0.00-6.92m9.28m36.00--0.9645-----0.0344-0.03440.000.04750.00----0.00-47.18-54.01-54.24-60.02------------0.00------52.35---26.64--
OptiBiotix Health PLC569.00k-2.98m12.24m5.00--1.66--21.52-0.0317-0.03170.00610.07520.06341.351.07113,800.00-33.2516.82-34.8517.5247.9853.03-524.43183.495.36-2.030.00100.1440.924.60-178.82------
Hemogenyx Pharmaceuticals PLC0.00-5.18m15.57m17.00--5.08-----0.0042-0.00420.000.00230.00----0.00-77.79-82.19-85.95-95.97-----------19.940.4794-------68.14--36.68--
Data as of Nov 12 2024. Currency figures normalised to Genflow Biosciences PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.15%Per cent of shares held by top holders
HolderShares% Held
Premier Fund Managers Ltd.as of 09 Apr 202432.00m9.15%
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.